Product Information
Registration Status: ActiveSIN13213P
XOLAIR 75MG POWDER AND SOLVENT FOR SOLUTION FOR INJECTION is approved to be sold in Singapore with effective from 2006-07-07. It is marketed by NOVARTIS (SINGAPORE) PTE LTD, with the registration number of SIN13213P.
This product contains Omalizumab 75mg in the form of INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION. It is approved for SUBCUTANEOUS use.
This product is manufactured by Novartis Pharma Stein AG in SWITZERLAND,Takeda Austria GmbH in FRANCE, andDELPHARM DIJON - QUETIGNY in AUSTRIA.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
A recombinant DNA-derived humanized IgG1k monoclonal antibody that selectively binds to human immunoglobulin E (IgE). Xolair is produced by a Chinese hamster ovary cell suspension culture in a nutrient medium containing the antibiotic gentamicin.
Indication
For treatment of asthma caused by allergies
Mechanism of Action
Xolair binds to IgE (a class of antibodies normally secreted in allergic responses), which prevents their binding to mast cells and basophils.
Active Ingredient/Synonyms
Omalizumab | Omalizumab |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.